Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma

Trevor J. Grant, Joshua A. Bishop, BLisa M. Christadore, Girish Barot, Hang Gyeong Chin, Sarah Woodson, John Kavouris, Ayesha Siddiq, Rachel Gredler, Xue Ning Shen, Jennifer Sherman, Tracy Meehan, Kevin Fitzgerald, Sriharsa Pradhan, Laura A. Briggs, William H. Andrews, Devanand Sarkar, Scott E. Schaus, Ulla Hansen

Research output: Contribution to journalArticlepeer-review

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Despite the prevalence of HCC, there is no effective, systemic treatment. The transcription factor LSF is a promising protein target for chemotherapy; it is highly expressed in HCC patient samples and cell lines, and promotes oncogenesis in rodent xenograft models of HCC. Here, we identify small molecules that effectively inhibit LSF cellular activity. The lead compound, factor quinolinone inhibitor 1 (FQI1), inhibits LSF DNA-binding activity both in vitro, as determined by electrophoretic mobility shift assays, and in cells, as determined by ChIP. Consistent with such inhibition, FQI1 eliminates transcriptional stimulation of LSF-dependent reporter constructs. FQI1 also exhibits antiproliferative activity in multiple cell lines. In LSF-overexpressing cells, including HCC cells, cell death is rapidly induced; however, primary or immortalized hepatocytes are unaffected by treatment with FQI1. The highly concordant structure-activity relationship of a panel of 23 quinolinones strongly suggests that the growth inhibitory activity is due to a single biological target or family. Coupled with the striking agreement between the concentrations required for antiproliferative activity (GI 50s) and for inhibition of LSF transactivation (IC 50s), we conclude that LSF is the specific biological target of FQIs. Based on these in vitro results, we tested the efficacy of FQI1 in inhibiting HCC tumor growth in a mouse xenograft model. As a single agent, tumor growth was dramatically inhibited with no observable general tissue cytotoxicity. These findings support the further development of LSF inhibitors for cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)4503-4508
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number12
DOIs
StatePublished - Mar 20 2012

Keywords

  • CP2
  • TFCP2
  • Transcription factor inhibitor
  • Xenograft tumor model

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this